Boeing, J&J Shares Flout Good Sense
|A glance at the charts of Boeing and Johnson & Johnson shows what stock-market bears are up against as they patiently await a meaningful correction of excesses that have been building in the financial system for nearly a decade. Are the portfolio managers who support these two stocks without a trace of nervousness crazy, or what? Boeing has received relentlessly negative press since December, and for good reason. Its huge fleet of 737 Max jets has been grounded for an overhaul of faulty navigation equipment that caused two crashes resulting in 346 deaths and a spate of lawsuits around the world. For its part, Johnson & Johnson just got socked with an $8 billion jury award that is not even related to the motherlode of lawsuits they will face because of talcum powder’s supposedly carcinogenic effects. The $8 billion verdict involved a guy who supposedly developed man-boobs after taking J&J’s antipsychotic drug Risperdal as a child. Boeing may be in slightly better shape, having made progress settling with the families of some of the passengers who died in the crashes. But other aggrieved families undoubtedly will seek jury trials that will leave the airline exposed to open-ended liabilities for the foreseeable future
Portfolio Omerta
And yet, the charts show that the shares of both companies have held up astoundingly well considering that their legal problems could drag on for years or even decades. After shaking out the weak hands, DaBoyz put the stocks back on their respective glide paths as though nothing of consequence had happened. Indeed, the stocks look capable of remaining buoyant more or less indefinitely, or at least until the inevitable bear market lays waste to all stocks. In the meantime, the omerta that binds those who make their living throwing Other People’s Money at a small handful of must-own stocks will prevail. A stampede out of Boeing and Johnson & Johnson shares in particular is coming, but not until a bull market that long ago took leave of its senses draws its last breath.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.